Immunotoxin Therapy in Treating Patients With Malignant Glioma

PHASE1/PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

October 31, 2000

Study Completion Date

March 31, 2005

Conditions
Brain and Central Nervous System Tumors
Interventions
BIOLOGICAL

cintredekin besudotox

DRUG

isolated perfusion

PROCEDURE

conventional surgery

Trial Locations (11)

30322

Winship Cancer Institute of Emory University, Atlanta

48202

Josephine Ford Cancer Center at Henry Ford Health System, Detroit

35294-3300

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham

33612-9497

H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

20892-1414

National Institute of Neurological Disorders and Stroke, Bethesda

02114

Massachusetts General Hospital Cancer Center, Boston

27157-1082

Comprehensive Cancer Center at Wake Forest University, Winston-Salem

19104-4283

Abramson Cancer Center at the University of Pennsylvania, Philadelphia

78284-7811

University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

New Approaches to Brain Tumor Therapy Consortium

OTHER

NCT00006268 - Immunotoxin Therapy in Treating Patients With Malignant Glioma | Biotech Hunter | Biotech Hunter